March 16, 2010 08:30 ET

MDRNA, Inc. to Report Fourth Quarter and Year-End 2009 Results on March 23, 2010 at 4:30 p.m. Eastern Time

BOTHELL, WA--(Marketwire - March 16, 2010) -  MDRNA, Inc. -- (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with investors and security analysts on Tuesday, March 23, 2010, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a business update and discuss financial results for the fourth quarter and fiscal year ended December 31, 2009.

To participate in the live conference call, U.S. residents should dial 800-573-4754 and international callers should dial 617-224-4325. The participant code for the live conference call is 37051807. To access the 24-hour telephone replay, U.S. residents should dial 888-286-8010 and international callers should dial 617-801-6888. The participant code for the replay is 99112425.

Alternatively, to access the live audio webcast for this conference call, please go to MDRNA's Web site at approximately 15 minutes prior to the conference call in order to register and download any necessary software. A replay of the webcast will be available for 30 days following the event.

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in oncology. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at

Contact Information